Clinical trials: Obesity Overweight
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)
To compare the effects of taranabant versus placebo on weight regain and weight maintenance after low calorie diet-induced weight loss in obese patients.
- Trial name
- NCT00420589
- Testing
- taranabant
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.
- Trial name
- NCT00131404
- Testing
- taranabant
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity (Disorder), Overweight , Obesity
I-OPERA: A European Study Testing a New Way to Do Health Research.
The goal of this observational pilot study is to evaluate whether a participant-mediated, direct-to-participant research approach is a feasible and effective way to collect health data from adults living with obesity in England…
- Trial name
- I-OPERA (NCT07759544)
- Volunteers
- 105 people
- Sponsor
- IQVIA RDS Spain, SL
Overweight, Obesity
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day.
- Trial name
- AMAZE 9 (NCT07720271)
- Testing
- zenagamtide
- Where
- 41 sites in United States
- Volunteers
- 950 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Obesity
Evaluation of the Tantalus System in Type 2 Diabetic Subjects
Metacure MC PT TAN2005-013 feasibility study is a prospective, multi-center, study to evaluate the safety and functionality of the TANTALUS System, in the treatment of obese T2DM patients, and to assess the effect of GCT …
- Trial name
- NCT00276471
- Testing
- Implantable pulse generator and electrodes
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- MetaCure Limited
Obesity
A Retrospective Chart Review of Three Medifast Weight Control Centers
The primary aim of this study is to to retrospectively evaluate the efficacy of the MWCC Jump Start (Medifast's 5 \& 1) Plan on the following indices: weight loss, anthropometric changes, and reduction in common markers of…
- Trial name
- NCT01662830
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Prader-Willi Syndrome
Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
This is a single-center, open-label, single-arm study with a double-blind, placebo-controlled, randomized withdrawal extension. Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are…
- Trial name
- NCT02034071
- Testing
- DCCR
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Essentialis, Inc.
Healthy
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with…
- Trial name
- NCT04903509
- Testing
- BI 1820237, Saxenda®, Paracetamol-ratiopharm®
- Where
- Germany
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
Benefit and Tolerability of IQP-AE-103 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03058367
- Testing
- IQP-AE-103 (330mg), IQP-AE-103 (165mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan.
- Trial name
- NCT06283641
- Testing
- Liraglutide
- Where
- 15 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients
1. Study Objective To assess the effect of HSG4112 on body weight To evaluate the safety and tolerability of HSG4112 2. Background Glaceum Inc.
- Trial name
- NCT05197556
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Glaceum
Obesity
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study…
- Trial name
- NCT00796367
- Testing
- VI-0521
- Volunteers
- 676 people
- Sponsor
- VIVUS LLC
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00104507
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Obesity Disease
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
- Trial name
- MARITIME-3-J (NCT06987695)
- Testing
- Maridebart cafraglutide
- Where
- 30 sites in Japan
- Volunteers
- 279 people
- Sponsor
- Amgen
Obesity, Weight Gain
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related…
- Trial name
- NCT06439277
- Testing
- Tirzepatide
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche